Excessive daytime sleepiness and 'sleep attacks' induced by entacapone

Fundamental and Clinical Pharmacology

Volumn 17, Issue 1, 2003, Pages 113-116

  Bareš, Martin ^a   Kaňovský, Petr ^a   Rektor, Ivan ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Daytime sleepiness; Entacapone; Parkinson's disease; Sleep attacks

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; TOLCAPONE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CASE REPORT; CIRCADIAN RHYTHM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DROP ATTACK; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; SLEEP DISORDER; SOMNOLENCE; WAKEFULNESS;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 0037323882     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00120.x     Document Type: Article

References (16)

1. Frucht A.J., Greene P.E., Fahn S. Sleep disorders in Parkinson's disease: a wake-up call. Mov. Disord. (2001) 15 601-603.
2. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52 1908-1910.
3. Ferreira J.J., Galitzky M., Montastruc J.L., Rascol O. Sleep attacks and Parkinson's disease treatment. Lancet (2000) 355 1333-1334.
4. Shapira A.H. Sleep attacks (sleep episodes) with pergolide. Lancet (2000) 355 1332-1333.
5. Hauser R.A., Gauger L., McDowell-Anderson W., Zesiewicz T.A. Pramipexol-induced somnolence and episodes of daytime sleep. Mov. Disord. (2000) 15 658-663.
6. Ferreira J., Thalamas C., Montastruc J.L., Castro-Caldas A., Rascol O, Levodopa monotherapy can induce 'sleep attacks' in Parkinson's disease patients. J. Neurol. (2001) 248 426-427.
7. Meyboom R.H.B, Hekster Y.A., Egberts A.C.G, Gribnau F.W.J, Edwards I.R. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Safety (1997) 17 374-389.
8. Tracik F., Ebersbach G. Sudden daytime sleep onset in Parkinson's disease: Polysomnographic recordings. Mov. Disord. (2001) 16 500-506.
9. Männistö P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. (1999) 51 593-628.
10. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs (2000) 59 1233-1250.
11. Dingemanse J. Catechol-O-methyltransferase inhibitors. Clinical potential in the treatment of Parkinson's disease. Drug. Dev. Res. (1997) 42 1-25.
12. Russ H., Muller T., Woitalla D., Rahbar A., Hahn J., Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 360 719-720.
13. Mercuri N.B., Federici M., Bernardi G. Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons, J. Neural. Transm. (1999) 106 1135-1140.
14. Hauser R.A., Molho E., Shale H., Pedder S., Dorflinger E.E., and the Tolcapone de Novo Study group. A pilot evaluation of the tolerabillty, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Mov. Disord. (1998) 13 643-647.
15. Dingemanse J. Issues important for rational COMT inhibition, in: Olanow W.C., Obeso J.A. (Eds), The role of COMT inhibitors in the treatment of Parkinson's disease. Neurology (2000) 55 (Suppl. 4), S24-31.
16. Johns M.W. New method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep (1991) 14 540-545.